Doripenem vs meropenem against Pseudomonas and Acinetobacter

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), is a significant healthcare-associated infection.
• Doripenem is a recently approved antibiotic for treating NP and VAP.
• Carbapenem resistance is a growing concern in treating Gram-negative bacterial infections.

Purpose of the Study:

• To compare the in vitro activity of doripenem and meropenem against clinical isolates from patients with nosocomial pneumonia.
• To evaluate the susceptibility patterns of Pseudomonas aeruginosa and Acinetobacter calcoaceticus-Acinetobacter baumannii complex to doripenem and meropenem.

Main Methods:

• Minimum Inhibitory Concentrations (MICs) were determined using the E-test method.
• The study analyzed 203 endotracheal aspirate isolates.
• Isolates included 140 Acinetobacter calcoaceticus-Acinetobacter baumannii complexes and 63 Pseudomonas aeruginosa.

Main Results:

• Doripenem exhibited significantly lower MIC 50 values against P. aeruginosa (0.38 mg/L) compared to meropenem (>32 mg/L), indicating 84.2-fold greater potency.
• MIC 50 and MIC 90 values for doripenem and meropenem were comparable against A. baumannii isolates.
• P. aeruginosa isolates demonstrated consistently higher susceptibility to doripenem than A. baumannii isolates.

Conclusions:

• Doripenem displays potent in vitro activity against P. aeruginosa, suggesting its potential as a treatment option for VAP caused by this pathogen.
• The study highlights differential activity of doripenem and meropenem against key Gram-negative pathogens implicated in nosocomial pneumonia.
• Further clinical studies are warranted to confirm the efficacy of doripenem in treating NP and VAP caused by P. aeruginosa and A. baumannii.